Global pharmaceutical companies are delaying the launch of new medicines in Europe as they navigate pricing uncertainties driven by U.S. policy changes under President Donald Trump. The U.S. government has been pushing to lower prescription drug costs by linking them to prices in other developed markets, particularly Europe, through a “most-favoured-nation” pricing model.